Tenaya Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
November 10, 2022 16:05 ET
|
Tenaya Therapeutics, Inc.
Extends Cash Runway to Mid-2024 Commenced Dosing in Phase 1 Clinical Trial of TN-301; Data Expected in 2023 Plans to Submit TN-201 IND by Year End SOUTH SAN FRANCISCO, Calif., Nov. 10, 2022 ...
Tenaya Therapeutics to Present Preclincial Study Data from TN-301 Program at the American Heart Association Scientific Sessions 2022
November 04, 2022 08:00 ET
|
Tenaya Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver...
Worldwide Precision Cardiology Industry to 2027 - by Offering, Sample Type, Technology, Application, End-user and Region
October 26, 2022 07:48 ET
|
Research and Markets
Dublin, Oct. 26, 2022 (GLOBE NEWSWIRE) -- The "Global Precision Cardiology Market: Competition Forecast and Opportunities to 2027" report has been added to ResearchAndMarkets.com's offering.The...
Tenaya Therapeutics to Participate in Inaugural Hypertrophic Cardiomyopathy Medical Society’s 2022 Scientific Sessions
September 29, 2022 08:00 ET
|
Tenaya Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver...
Tenaya Therapeutics to Participate in Upcoming October Investor and Industry Conferences
September 29, 2022 07:45 ET
|
Tenaya Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver...
Tenaya Therapeutics to Participate in Upcoming September Investor Conferences
September 06, 2022 16:05 ET
|
Tenaya Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver...
Tenaya Therapeutics Announces FDA Clearance of Investigational New Drug Application and Initiation of Phase 1 Safety Study for TN-301, an HDAC6 Inhibitor for Heart Failure with Preserved Ejection Fraction
September 06, 2022 08:00 ET
|
Tenaya Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a biotechnology company with a mission to discover, develop and deliver potentially curative...
Tenaya Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update
August 10, 2022 16:01 ET
|
Tenaya Therapeutics, Inc.
Received State Licensing to Enable cGMP Manufacturing of Drug Product TN-201 and TN-301 IND Submissions on Track for Second Half 2022 Presented Preclinical Data for Multiple Pipeline Programs and...
Tenaya Therapeutics Publishes Preclinical Data in Science Translational Medicine Detailing Discovery of HDAC6 Inhibitor for Treatment of Heart Failure
July 06, 2022 14:00 ET
|
Tenaya Therapeutics, Inc.
Tenaya’s Precision Medicine Platform Used to Identify HDAC6 Target Using Phenotypic Screening and Machine Learning Algorithms Tenaya’s HDAC6 Inhibitor TN-301 Advancing to the Clinic for HFpEF, with...
Aortic Valve Replacement Market Size is projected to reach USD 33.51 Billion by 2030, growing at a CAGR of 14%: Straits Research
June 21, 2022 09:00 ET
|
Straits Research
New York, United States, June 21, 2022 (GLOBE NEWSWIRE) -- The main thing driving the aortic valve replacement market is the growing number of valvular diseases like aortic stenosis and aortic...